Good pick for ABBV

Article Excerpt

ABBVIE INC., $179.86, is a buy. The company (New York symbol ABBV; TSINetwork Rating: Above Average) (www.abbvie.com; Shares outstanding: 1.8 billion; Market cap: $319.6 billion; Dividend yield: 3.5%) continues to hit new, all-time highs—and the stock is now up 84.1% since we first recommended it in our August 2020 issue at $97.70. Abbott Labs spun off AbbVie in 2013. Richard Gonzalez, 70, and the CEO since the spinoff, is now resigning. Notably, during Gonzalez’s decade in leadership, AbbVie nearly tripled its sales revenue. The company is now appointing chief operating officer Robert Michael to succeed Gonzalez as the drugmaker’s second-ever CEO on July 1, 2024. Michael, 53, has played a part in AbbVie’s growth since its formation, and we think the smooth transition bodes well for AbbVie’s future success and its stock price. AbbVie Inc. is still a buy. buy…